Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2016

View Archived Issues

First viable murine model of cblC type CMAH reported

Biallelic mutations in PPA2 are associated with mitochondrial dysfunction

Highland Therapeutics enters agreement for IBD drug candidate

Novel ciclosporin formulation PADciclo may allow lower doses for treating dry eye

Durable responses seen with oncolytic adenovirus CG-0070 in phase II/II bladder cancer trial

Australian institutions sign MOU to establish Australian Hepatitis C Elimination Program

Anti-sFlt-1 MAb preserves normal lung structure and prevents pulmonary hypertension in models of BPD

Merck & Co. receives positive opinion for Zepatier in the E.U.

Checkpoint Therapeutics signs BET inhibitor license agreements with Jubilant and TG Therapeutics

Humira receives CHMP positive opinion to treat certain forms of noninfectious uveitis

ConverGene patents inhibitors of bromodomain-containing proteins

H. Lundbeck discloses BACE1 inhibitors

FORGE Life Science develops antivirals

Romark Laboratories presents prodrugs of tizoxanide

FDA approves Zinbryta as once-monthly treatment for relapsing MS

Shanghai Shaletech Technology announces EGFR inhibitors

EMA begins review of guidelines governing first-in-human trials

European Commission approves Strimvelis for ADA-SCID

FDA grants accelerated approval to Ocaliva for primary biliary cholangitis

EMA's CHMP gives positive opinion on brentuximab vedotin for post-transplant Hodgkin's lymphoma

FDA approves Axumin to detect recurrent prostate cancer

EMA committee does not support approval of Ninlaro capsules

EMA committee recommends approval of Epclusa for hepatitis C

Saxagliptin/dapagliflozin receives positive opinion in E.U.

EMA committee hands down positive opinion to extend Kyprolis indication

FDA grants orphan drug designation to Portage's BHV-4157

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...